Work

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

Year: 2025

Type: article

Abstract: OBJECTIVES: HIV-1 RNA and temsavir plasma concentration were associated with virologic response through 24 weeks. This expanded analysis evaluated predictors of the durability of response at Weeks 96 and 192. METHODS: BRIGHTE participant data (Randomized Cohort [RC], n = 272; Non-randomized Cohort, n = 99) were evaluated to examine baseline factors associated with virologic outcomes (HIV-1 RNA <40 copies/mL [Snapshot]; protocol-defined virologic failure [PDVF]) using linear/logistic regression with stepwise selection. A separate analysis evaluated baseline factors for association with treatment-adherent PDVF. RESULTS: , HIV-1 RNA ≥100 000 copies/mL, antiretroviral therapy duration >20 years or gp120 substitutions, had low predictive value for treatment-adherent PDVF in RC participants (Week 96, 35%; Week 192, 39%). CONCLUSIONS: Multivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV-1.

Source: HIV Medicine

DOI: 10.1111/hiv.70154